





PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q75927

Ryuichi MORISHITA, et al.

Appln. No.: 10/615,292

Group Art Unit: 1636

Confirmation No.: 7040

Examiner: Robert M. Kelly

Filed: July 9, 2003

For:

MEDICAMENT COMPRISING HGF GENE

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In the Office Action dated December 30, 2005, the Examiner has identified the application as containing claims directed to distinct species.

The Examiner has required Applicants to elect a single disclosed species for prosecution on the merits. The Examiner believes claim 7 is generic.

In response to the Election of Species Requirement, Applicants elect the restenosiscausing condition of myocardial infarction, without traverse.

Applicant was also advised that a response to this requirement must include a listing of all claims readable on the elected species.

Applicants note that claims 7, 8, and 9 are readable on the elected species.

RESPONSE TO ELECTION OF SPECIES REQUIREMENT

U.S. Appln. No.: 10/615,292

Atty. Docket No.: Q75927

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 56,704

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: January 30, 2006